HDRPF Stock Chart & Stats
$0.01
<$0.01(614.29%)
At close: 4:00 PM EDT
$0.01
<$0.01(614.29%)
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
$6.76M
Enterprise Value$15.81M
Total Cash (Recent Filing)$1.29M
Total Debt (Recent Filing)$8.69M
Price to Earnings (P/E)83.3
Beta1.13
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding389,104,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)6.55
Price to Sales (P/S)1.33
P/FCF Ratio-3.80
Enterprise Value/Market Cap2.34
Enterprise Value/Revenue0.78
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda-22.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ExpansionThe rebound in revenue and gross margin indicates stronger operating scale and improved unit economics. If maintained, this combination can support better earnings conversion, provide more resources for reinvestment, and strengthen the company’s position in specialty and generic pharmaceuticals over the next several quarters.
Positive Cash-flow TurnaroundThe shift to positive operating and free cash flow is an important improvement in financial quality, showing that the business is beginning to generate cash internally. Sustained cash generation could reduce funding dependence, support obligations, and give management greater flexibility to execute its strategy.
Leverage ReductionThe substantial reduction in debt-to-equity shows progress toward a more stable capital structure, even though leverage remains high. Continued balance-sheet repair would lower financial risk, improve resilience if operating conditions weaken, and potentially expand the company’s capacity to fund growth internally.
Bears Say
Operating Profitability Remains WeakThe company has not yet demonstrated durable operating profitability despite its revenue and gross-margin recovery. Negative EBIT and EBITDA indicate that overhead and operating costs still absorb gross profit, leaving limited protection against execution setbacks and making future earnings dependent on further improvement.
High Leverage And Thin Obligation CoverageHigh leverage combined with thin cash-flow coverage leaves limited financial buffer while profitability is still fragile. Even with improving cash generation, the business may have less flexibility to absorb weaker earnings, meet obligations comfortably, or invest in growth without relying on additional financing.
Unproven Profitability DurabilityThe extended record of losses and deeply negative margins shows that the recent improvement has not yet been validated across a full operating cycle. This history raises the risk that earnings gains may prove temporary, particularly if revenue growth slows or margin expansion fails to continue.
Epsilon Healthcare Limited News
HDRPF FAQ
What was Epsilon Healthcare Limited’s price range in the past 12 months?
Epsilon Healthcare Limited lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Epsilon Healthcare Limited’s market cap?
Epsilon Healthcare Limited’s market cap is $6.76M.
When is Epsilon Healthcare Limited’s upcoming earnings report date?
Epsilon Healthcare Limited’s upcoming earnings report date is Feb 26, 2027 which is in 135 days.
How were Epsilon Healthcare Limited’s earnings last quarter?
Epsilon Healthcare Limited released its earnings results on Aug 31, 2026. The company reported -$0.001 earnings per share for the quarter.
Is Epsilon Healthcare Limited overvalued?
According to Wall Street analysts Epsilon Healthcare Limited’s price is currently Overvalued.
Does Epsilon Healthcare Limited pay dividends?
Epsilon Healthcare Limited does not currently pay dividends.
What is Epsilon Healthcare Limited’s EPS estimate?
Epsilon Healthcare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epsilon Healthcare Limited have?
Epsilon Healthcare Limited has 389,104,000 shares outstanding.
What happened to Epsilon Healthcare Limited’s price movement after its last earnings report?
Epsilon Healthcare Limited reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Epsilon Healthcare Limited?
Currently, no hedge funds are holding shares in HDRPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Epsilon Healthcare Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
3.34%
Trailing 12-Months
Asset Growth
121.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Epsilon Healthcare Limited
Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manufacturing and distributing a range of hydroponic supplies, including equipment, materials, and vital nutrients; developing and providing medicinal cannabis products; and offering comprehensive, ready-to-implement solutions for cannabis cultivation. The company officially rebranded from THC Global Group Limited to Epsilon Healthcare Limited in February 2021.
Technical Analysis
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―